Business Standard

Gland Pharma receives Sebi's go-ahead to launch IPO pegged at Rs 5,000 cr

Apart from the fresh issue, there is an offer for sale (OFS) of a little over 34 million shares as part of the IPO

IPO
Premium

The Hyderabad-based company, backed by China's Fosun Pharma, develops, manufactures and markets complex injectables

Press Trust of India
Gland Pharma has received capital markets regulator Sebi's go-ahead to launch an initial public offering (IPO) that includes fresh issue of shares worth up to Rs 1,250 crore. According to investment banking sources, the IPO would be worth over Rs 5,000 crore. 
 
Apart from the fresh issue, there is an offer for sale (OFS) of a little over 34 million shares as part of the IPO.
 
The Hyderabad-based company, backed by China's Fosun Pharma, develops, manufactures and markets complex injectables.
 
The company filed draft papers in July and obtained Sebi's observation on October 19 to float an IPO, an update

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 27 2020 | 12:37 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com